Quarterly ResultAug 12, 2026, 08:08 AM
Century Therapeutics Q2 Net Loss $34.55M; Secures $126.4M PIPE Financing
AI Summary
Century Therapeutics reported a net loss of $34.55 million for the second quarter of 2026 and $56.20 million for the first six months, with no collaboration revenue. The company utilized $45.10 million in cash from operating activities during the six-month period. A significant positive was the completion of a Private Investment in Public Equity (PIPE) offering, which generated $126.39 million in net proceeds, bolstering the company's financial position. As of June 30, 2026, cash and investments totaled $197.19 million, providing liquidity for at least the next 12 months.
Key Highlights
- Net loss for Q2 2026 was $34.55 million, compared to $32.54 million in Q2 2025.
- Net loss for the first six months of 2026 was $56.20 million.
- No collaboration revenue was reported for Q2 or H1 2026, down from $109.16 million in H1 2025.
- Net cash used in operating activities for H1 2026 was $45.10 million.
- Secured $126.39 million in net proceeds from a Private Investment in Public Equity (PIPE) offering.
- Cash and cash equivalents and investments totaled $197.19 million as of June 30, 2026.
- Total stockholders' equity increased to $232.35 million at June 30, 2026.
- Incurred an $11.15 million loss on lease component termination in Q2 2026.
Price Impact
More from IPSC